Neuroendocrine Carcinomas clinical trials

Explore recruiting neuroendocrine carcinomas clinical trials.

Recruiting neuroendocrine carcinomas studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Neuroendocrine Carcinomas trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Phase II Study Of Tarlatamab Alone Or In Combination With Chemotherapy In Advanced Neuroendocrine Carcinomas Of The Digestive System Or Unknown Primary Origin

Spain, France

Therapeutic exploratory (Phase II) EU CTIS Study details

Phase II study to evaluate the efficacy of 12-month neoadjuvant chemotherapy in terms of disease-free survival in patients with localized digestive neuroendocrine carcinomas - NEONEC D19-01

France

Therapeutic exploratory (Phase II) EU CTIS Study details

Phase II study to evaluate the efficacy of 12-month neoadjuvant chemotherapy in terms of disease-free survival in patients with localized digestive neuroendocrine carcinomas - NEONEC D19-01

France

Therapeutic exploratory (Phase II) EU CTIS Study details

GCO-003 TARLANEC A randomized phase III trial study comparing tarlatamab with standard of care chemotherapy in patients with pre-treated advanced, refractory pulmonary or gastroenteropancreatic poorly differentiated neuroendocrine carcinomas

France

Therapeutic confirmatory (Phase III) EU CTIS Study details

Multicenter, open label, single arm, phase II study to assess the efficay and safety of enfortumab-vedotin (EV) as a single agent in patients with advanced Neuroendocrine Carcinomas (NEC) refractory or ineligible to platinum-containing chemotherapy

Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

A study to evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and preliminary Anti-Tumor activity of RO7616789 in participants with Advanced Small Cell Lung Cancer and other Neuroendocrine Carcinomas

Denmark, Poland, Spain, Germany, France

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

Neuroendocrine Carcinomas trials by city

Neuroendocrine Carcinomas in Toronto Neuroendocrine Carcinomas in Vancouver Neuroendocrine Carcinomas in Montreal Neuroendocrine Carcinomas in Calgary Neuroendocrine Carcinomas in Edmonton Neuroendocrine Carcinomas in Ottawa Neuroendocrine Carcinomas in Winnipeg Neuroendocrine Carcinomas in Quebec City Neuroendocrine Carcinomas in Hamilton Neuroendocrine Carcinomas in Kitchener Neuroendocrine Carcinomas in London Neuroendocrine Carcinomas in Halifax Neuroendocrine Carcinomas in New York Neuroendocrine Carcinomas in Los Angeles Neuroendocrine Carcinomas in Chicago Neuroendocrine Carcinomas in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease